Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RESEARCH TOOLSreports
RVPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $4.45
Previous CloseN/A
Volume1.63M
Average Volume (3M)1.82M
Market Cap
$75.92M
Enterprise Value$43.20M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 24, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding46,579,200
10 Day Avg. Volume1,601,418
30 Day Avg. Volume1,824,630
Standard Deviation0.47
R-Squared0.00018
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$8.33Price Target Upside430.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Reviva Pharmaceuticals Holdings News
PremiumCompany Announcements
Reviva Pharmaceuticals Approves Executive Compensation Changes
PremiumCompany Announcements
Reviva Pharmaceuticals Strengthens Financial Position with Offering---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe preliminary data from the OLE study further strengthens the body of data on safety, efficacy, and treatment adherence for brilaroxazine, representing a catalyst for RVPH shares.
Drug EfficacyBrilaroxazine's positive Phase 3 data demonstrates its impact on positive, negative, and cognition symptoms in schizophrenia patients with an effect size greater than many antipsychotics.
Bears Say
Funding ConstraintsFunding constraints have delayed the P3 launch and management is yet to address capital.
---
Ownership Overview
4.51%
Insiders
2.72% Mutual Funds
0.26% Other Institutional Investors
89.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.60 and its highest was $4.45 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $75.92M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 24, 2025 which is in 29 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Nov 14, 2024. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.006.
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.22.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 46,579,200 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -7.438%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in RVPH
---
Reviva Pharmaceuticals Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (430.57% Upside)
$8.33 (430.57% Upside)
Blogger Sentiment
Bullish
RVPH Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 684.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-63.05%
12-Months-Change
Fundamentals
Return on Equity
334.44%
Trailing 12-Months
Asset Growth
41.63%
Trailing 12-Months
Company Description
Reviva Pharmaceuticals Holdings
Tenzing Acquisition Corp. is a blank check company, which engages in the acquisition of similar business combination with one or more businesses and entities. It focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction. The company was founded on March 20, 2018 and is headquartered in New York, NY.
---
RVPH Stock 12 Month Forecast
Average Price Target
$8.33
▲(430.57% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Viking Therapeutics
―
Xenon
―
Axsome Therapeutics
―
Best Analysts Covering RVPH
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-39.84%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -39.84% per trade.
---